Eclipse Surgical PTMR PMA Application Planned For Fourth Quarter
This article was originally published in The Gray Sheet
Executive Summary
Eclipse Surgical Technologies is planning a fourth-quarter premarket approval application submission to FDA for its minimally invasive percutaneous transmyocardial revascularization (PTMR) holmium laser system for treatment of angina patients not amenable to conventional treatment.
You may also be interested in...
Eclipse Surgical TMR Laser Shipments Commence Following FDA Approval
Shipments of Eclipse Surgical Technologies' Eclipse 2000 transmyocardial revascularization laser system began "immediately" following FDA approval, announced Feb. 11, at a price of $295,000 each, according to the firm.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.